02563.HK
Beijing Biostar Pharms Co Ltd
HKSE · Healthcare · Drug Manufacturers - General · CN
HKD 3.72
−0.27%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 64.6M | 37.1M | 77.9M | 73.8M | 37.4M |
| Cost of Revenue | 4.9M | 2.9M | 15.4M | 21.9M | 10.2M |
| Gross Profit | 59.7M | 34.2M | 62.5M | 51.8M | 27.2M |
| Operating Expenses | |||||
| R&D Expense | 72.5M | 92.3M | 123.7M | 140.1M | 70.1M |
| SG&A Expense | 42.6M | 42.5M | 44.5M | 154.2M | 116.4M |
| General & Admin Expense | 19.5M | 15.3M | 8.6M | 48.6M | 36.6M |
| Selling & Marketing Expense | 22.6M | 27.3M | 35.9M | 105.6M | 79.7M |
| Other Expenses | 70.8M | 48.8M | 49.8M | (1.1M) | 68.6M |
| Total Operating Expenses | 185.9M | 183.7M | 218.0M | 293.1M | 255.1M |
| Cost and Expenses | 190.8M | 186.6M | 262.3M | 315.0M | 265.3M |
| Operating Income (EBIT) | (126.2M) | (151.4M) | (184.4M) | (241.3M) | (227.9M) |
| Non-Operating | |||||
| Interest Income | — | 5.1M | 5.2M | 14.5M | 3.8M |
| Interest Expense | — | 102.8K | 119.2K | 63.1K | 80.9K |
| Net Interest Income | 18.5M | 5.0M | 5.0M | 14.5M | 3.7M |
| Other Non-Op Income/Expense | 1.6M | 8.8M | 28.5M | 31.4M | 45.1M |
| Non-Operating Income (excl Interest) | (8.1M) | (3.3M) | 894.5K | (31.4M) | (45.2M) |
| EBT (Pre-Tax Income) | (124.6M) | (142.5M) | (155.9M) | (209.9M) | (182.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (124.6M) | (142.5M) | (155.9M) | (209.9M) | (182.8M) |
| Earnings from Cont. Ops | (124.6M) | (142.5M) | (155.9M) | (209.9M) | (182.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (124.6M) | (142.5M) | (155.9M) | (209.9M) | (182.8M) |
| Per Share | |||||
| Basic EPS | (HK$0.34) | (HK$0.39) | (HK$0.43) | (HK$0.58) | (HK$0.50) |
| Diluted EPS | (HK$0.34) | (HK$0.39) | (HK$0.43) | (HK$0.58) | (HK$0.50) |
| Revenue Per Share | HK$0.18 | HK$0.10 | HK$0.21 | HK$0.20 | HK$0.10 |
| Shares | |||||
| Basic Shares Outstanding | 364.6M | 365.1M | 364.6M | 364.6M | 364.6M |
| Diluted Shares Outstanding | 364.6M | 365.1M | 364.6M | 364.6M | 364.6M |
| Profitability Metrics | |||||
| EBITDA | (106.1M) | (139.9M) | (173.7M) | (198.1M) | (170.8M) |
| D&A | 12.0M | 11.5M | 10.6M | 11.8M | 12.0M |
| EBIT | (118.0M) | (151.4M) | (184.4M) | (209.8M) | (182.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026